We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Fig. 1.

Fig. 1. From: Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Average time–activity curves for the first 60 min after injection. Data are shown for mice injected with 64Cu (A), 64Cu-labeled DOTA (B), 64Cu-labeled DOTA-siRNA (C), and Tf-targeted nanoparticles containing 64Cu-labeled DOTA-siRNA (D). Error bars indicate SE.

Derek W. Bartlett, et al. Proc Natl Acad Sci U S A. 2007 September 25;104(39):15549-15554.
2.
Fig. 2.

Fig. 2. From: Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Tissue distribution of 64Cu-DOTA-siRNA delivered by targeted (Tf) and nontargeted (PEG) nanoparticles. (A) Fused micro-PET/CT images of mice at 1, 10, and 60 min after injection. (B) Blood clearance and tumor localization of Tf-targeted and nontargeted siRNA nanoparticles.

Derek W. Bartlett, et al. Proc Natl Acad Sci U S A. 2007 September 25;104(39):15549-15554.
3.
Fig. 4.

Fig. 4. From: Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Analysis of the interplay between the EPR effect and tumor-specific targeting, using a three-compartment model. (A) Model schematic and governing equations to estimate tumor uptake. (B) Model fit for total tumor uptake (Total) from experimental data (Exp) in Fig. 2, using k21 = k23 = 0. C2 is the concentration in compartment 2. (C) Effect of tumor clearance (k21) and tumor-specific binding/uptake (k23) on tumor accumulation 1 d after injection.

Derek W. Bartlett, et al. Proc Natl Acad Sci U S A. 2007 September 25;104(39):15549-15554.
4.
Fig. 3.

Fig. 3. From: Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Multimodality in vivo imaging of siRNA nanoparticle delivery and function, using micro-PET/CT and BLI. (A) Fused micro-PET/CT images showing tumor-associated (arrow) activity 1 d after injection of targeted (Tf) and nontargeted (PEG) nanoparticles containing 64Cu-DOTA-siRNA. (B) BLI of the same mice shown in A before injection and 1 d after injection. (C) Relative change in luciferase expression 1 d after injection of Tf-targeted (Tf, n = 7) and nontargeted (PEG, n = 4) nanoparticles containing 64Cu-DOTA-siRNA for simultaneous PET imaging. Error bars indicate SE.

Derek W. Bartlett, et al. Proc Natl Acad Sci U S A. 2007 September 25;104(39):15549-15554.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk